why choose us

300×250 Ad Slot

Research Article: Clinical outcomes and bleeding events associated with tirofiban combined with intravenous alteplase in acute ischaemic stroke: a retrospective single-center study

Date Published: 2026-07-10

Abstract:
To evaluate the clinical efficacy and bleeding risk of tirofiban combined with intravenous alteplase in patients with acute ischaemic stroke (AIS). This retrospective study identified 90 AIS patients who were divided according to the treatment received into a combined group (CG, n =?45; tirofiban plus alteplase) and an alteplase group (AG, n =?45; alteplase alone). The 90-day modified Rankin Scale outcome was defined as the primary outcome, whereas neurological deficits, coagulation parameters, inflammatory biomarkers, post-treatment vascular status, activities of daily living, and bleeding events were evaluated as secondary or exploratory outcomes. Baseline characteristics were comparable between the two groups ( p >?0.05). NIHSS scores in the CG were significantly lower than in the AG at 24?h, 7?days, and 14?days after treatment (all p <?0.01). Post-treatment PT, APTT, and D-dimer were higher in the CG, while fibrinogen was lower (all p <?0.001). At day 7, hs-CRP, IL-6, and TNF- ? were significantly lower in the CG (all p?<?0.001). The CG had a higher rate of favorable post-treatment vascular status ( ? 2 =?4.731, p =?0.030), a higher proportion of favorable 90-day outcomes defined as mRS???2 ( ? 2 =?5.414, p =?0.020), and higher Barthel Index scores at day 14 ( p <?0.001). The total bleeding rate was 28.89% in the CG and 17.78% in the AG, with no statistically significant between-group difference ( ? 2 =?1.543, p =?0.214). In this retrospective single-center cohort, tirofiban combined with alteplase was associated with lower NIHSS scores, better post-treatment vascular status, and higher rates of favorable 90-day outcomes, suggesting that combination therapy may potentially improve neurological recovery, attenuate inflammation, and optimize post-treatment vascular status in patients with AIS; however, these findings require confirmation in larger randomized trials.

Introduction:
Acute ischaemic stroke (AIS) is one of the most common neurological emergencies, accounting for approximately 60–80% of all stroke cases, and is associated with persistently high rates of disability and mortality ( 1 , 2 ). The core pathophysiological mechanism of AIS is ischaemic neuronal necrosis resulting from acute cerebral arterial occlusion; early restoration of cerebral perfusion is therefore fundamental to improving patient outcomes ( 3 ). Intravenous alteplase (rt-PA) thrombolysis currently constitutes an…

Read more

300×250 Ad Slot